Douglas Brust
Infectious Disease · Miami, FLNPI 1134178791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $288,283 of the $359,199 with a category attached, or 80.3%. Gilead accounts for 68.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $92,284 and has fallen 54.5% since, to $41,969 in 2025. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 606 payments — averaging $592.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$244K
- Viiv Healthcare Company$109K
- Astellas Pharma US Inc$2K
- Merck$1K
- Johnson & Johnson$406
- Theratechnologies Inc.$326
- plus $920 from 12 others
Across 7 payments — averaging $15,360 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$99K
- Viiv Healthcare Company$8K
What the payments were for
- Consulting fees$16,8955%
- Speaking & faculty fees$288,28380%
- Travel & lodging$39,28411%
- Food & beverage$14,6754%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 310 | $244,497 |
| Viiv Healthcare Company | 192 | $109,270 |
| Astellas Pharma US Inc | 2 | $2,385 |
| Merck | 31 | $1,394 |
| Johnson & Johnson | 33 | $406 |
| Theratechnologies Inc. | 18 | $326 |
| Penumbra, Inc. | 2 | $224 |
| Aroa Biosurgery Incorporated | 1 | $135 |
| Endologix LLC | 1 | $119 |
| Integra Lifesciences Corporation | 1 | $104 |
| EMD Serono, Inc. | 4 | $98 |
| Janssen Products, LP | 2 | $61 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| AbbVie | 2 | $45 |
| Janssen Scientific Affairs, LLC | 2 | $29 |
| Exact Sciences | 1 | $29 |
| Lilly USA, LLC | 1 | $16 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$122,188
- DOVATO$62,922
- Descovy$53,812
- RUKOBIA$28,635
- Truvada$17,170
- Sunlenca$7,232
- Epclusa$6,912
- Yeztugo$3,308
- CRESEMBA$2,385
- Indigo System$224
- CABENUVA$123
- AFX2 Bifurcated Endograft System$119
- INTEGRA MESHED BILAYER WOUND MATRIX$104
- INTEGRA WOUND MATRIX (IWM)$104
- PRIMATRIX$104
- INTEGRA DERMAL REGENERATION TEMPLATE$104
- INTEGRA FLOWABLE WOUND MATRIX$104
How this compares
$359,199 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 31 | $117,783 |
| Rosuvastatin Calcium | 17 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $244,497 | $117,78331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Vanessa SilebiMiami$32K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
- Lennox ArchibaldGainesville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.